01PEPTIDE
Retatrutide
An investigational GIP, GLP-1 and glucagon receptor agonist studied for obesity and metabolic outcomes.
Weight ManagementAppetiteGlucose / Insulin
EXPLORE THIS GOAL · MW
Fat Loss research
Fat Loss records within Metabolic + Weight. Structured links are generated from shared research-goal tags.
01
Relevant peptides
02PEPTIDE
Tirzepatide
An approved dual GIP and GLP-1 receptor agonist studied across type 2 diabetes, obesity and cardiometabolic outcomes.
Weight ManagementAppetiteGlucose / Insulin
03PEPTIDE
Semaglutide
An approved GLP-1 receptor agonist with formulation- and indication-specific evidence for diabetes, weight management and cardiovascular outcomes.
Weight ManagementAppetiteGlucose / Insulin
04PEPTIDE
Cagrilintide
An investigational long-acting amylin analogue studied alone and with semaglutide for weight management.
Weight ManagementAppetiteFat Loss
05PEPTIDE
CagriSema
An investigational fixed combination of cagrilintide and semaglutide studied in metabolic and weight-management trials.
Weight ManagementAppetiteGlucose / Insulin
06PEPTIDE
Tesamorelin
A GHRF analogue approved for reduction of excess abdominal fat in adults with HIV and lipodystrophy, with additional research contexts.
Body CompositionFat LossNeuroendocrine
07PEPTIDE
AOD-9604
A modified growth-hormone fragment studied in metabolic and obesity research, with limited supportive clinical efficacy data.
Fat LossWeight ManagementBody Composition
08PEPTIDE
5-Amino-1MQ
A small-molecule NNMT inhibitor studied primarily in preclinical metabolic and adipose-tissue models.
Fat LossBody CompositionMetabolic
09PEPTIDE
Survodutide
An investigational GLP-1 and glucagon receptor dual agonist in clinical development for obesity and metabolic liver disease.
Weight ManagementAppetiteFat Loss
10PEPTIDE
Mazdutide
A GLP-1 and glucagon receptor dual agonist studied in obesity and type 2 diabetes, with development and regulatory status varying by region.
Weight ManagementGlucose / InsulinFat Loss
11PEPTIDE
Pemvidutide
An investigational GLP-1 and glucagon receptor dual agonist studied for obesity and metabolic liver disease.
Weight ManagementFat LossBody Composition
12PEPTIDE
Liraglutide
An approved daily GLP-1 receptor agonist studied for type 2 diabetes, weight management and cardiovascular outcomes.
Weight ManagementAppetiteGlucose / Insulin
02
Related protocols
03
Popular comparisons
04
Related research
SPONSOR UPDATETRIUMPH-1 Phase 3 topline resultsRetatrutide · Eli Lilly and Company · 2026SPONSOR UPDATETRIUMPH-2 and TRIUMPH-3 Phase 3 topline results and planned regulatory submissionRetatrutide · Eli Lilly and Company · 2026REGULATORYWhat to know about retatrutideRetatrutide · Eli Lilly and Company · 2026CLINICAL TRIALCoadministered Cagrilintide and Semaglutide in Adults with Overweight or ObesityCagriSema · New England Journal of Medicine · 2025CLINICAL TRIALTriple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver diseaseRetatrutide · Nature Medicine · 2024CLINICAL TRIALGlucagon and GLP-1 receptor dual agonist survodutide for obesitySurvodutide · The Lancet Diabetes & Endocrinology · 2024
05
Tools
06
Related goals
BUILD FROM THIS RESEARCH CONTEXT
Build a stack for Fat Loss
The goal stays visible in the stack builder. Related records are suggestions by tag overlap; you choose what to add.